InspireMD, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NSPR research report →
Range $3 – $6
Price Chart
About the company
InspireMD, Inc. , an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases.
- CEO
- Marvin L. Slosman
- IPO
- 2011
- Employees
- 127
- HQ
- Miami, FL, US
Get TickerSpark's AI analysis on NSPR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $29.23M
- P/E
- -1.21
- PEG
- -0.02
- P/S
- 2.77
- P/B
- 2.13
- EV/EBITDA
- -0.36
- Div Yield
- 0.00%
- Gross Margin
- 12.62%
- Op Margin
- -477.84%
- Net Margin
- -336.72%
- ROE
- -93.52%
- ROIC
- -193.80%
Latest fiscal year · YoY change
- Revenue
- $8.98M+28.1%
- Gross Profit
- $2.65M+75.9%
- Op Income
- $-49,112,000
- Net Income
- $-48,786,000-52.4%
- EPS
- $-0.76+0.0%
- OCF Growth
- -60.5%
- FCF Growth
- -58.0%
- 52W High
- $2.17
- 52W Low
- $0.43
- 50D MA
- $0.61
- 200D MA
- $1.00
- Beta
- 0.91
- RSI (14)
- 44
- Avg Volume
- 234.68K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
InspireMD said Q3 was a turning point, highlighted by FDA approval of CGuard Prime for TCAR, while revenue remained subdued due to the prior U.S. market withdrawal and the company launched a new financing process.· November 12, 2026
- FDA approved CGuard Prime for TCAR, which management said expands the U.S. addressable market by about 40,000 annual procedures.
- Q3 total revenue was $2.2 million, down 11% year over year, while international revenue rose 9% to $2.2 million.
- Gross profit was $0.2 million, or 10.7% of revenue, versus $0.9 million and 34.2% a year ago.
- Operating expenses fell 27% to $10.2 million, helped by a workforce reduction of about 20%.
- Management said product is already shipping for TCAR and expects FDA feedback on the legacy CGuard CAS system by year-end, with CGUARDIANS III targeted for end-2027.
Total revenue in Q3 2026 was $2.2 million, down $0.3 million, or 11%, from Q3 2025. International revenue was $2.2 million, up $0.2 million, or 9% year over year, and was up 10% on a constant-currency basis; U.S. sales were about $32,000. Gross profit was $0.2 million, or 10.7% of revenue, versus $0.9 million, or 34.2%, a year earlier. Operating expenses were $10.2 million, down $3.7 million, or 27%, and net loss was $9.8 million, or $0.12 per share, versus $12.7 million, or $0.17 per share, last year. Cash and cash equivalents plus marketable securities were $19.2 million at September 30, 2026, versus $54.2 million at year-end 2025. Management did not give formal revenue or EPS guidance, but said it expects FDA feedback on the legacy CGuard system by the end of the year, anticipates submitting the CGuard Prime 135 CAS delivery system before year-end, expects reentry in the first half of 2027 subject to review, and continues to target end-2027 approval for CGUARDIANS III.
Marvin Slosman framed the quarter as a major inflection point, calling the FDA approval of CGuard Prime for TCAR one of the most significant milestones in the company’s history. He emphasized that InspireMD is moving from regulatory progress back into U.S. commercial execution, with a focus on physician adoption, account planning, and a broader carotid platform spanning TCAR and CAS. His tone was upbeat and confident, but he repeatedly noted that meaningful work remains and that success will depend on disciplined execution.
Mike Lawless focused on the financial cleanup and the cost structure reset. He said Q3 revenue was held back by the temporary U.S. withdrawal, while gross margin also suffered from lower international ASPs; operating expenses fell to $10.2 million partly because of a one-time $1.8 million reversal of stock-comp expense tied to headcount reductions. He added that the workforce reduction should drive incremental savings starting in Q4 and into the first several quarters of next year, with some reinvestment in sales and marketing possible later depending on the commercial ramp and CGuard Prime 80 launch.
Analysts focused on how quickly the new TCAR approval could translate into shipments and uptake, with questions about VAC committee approvals, inventory, and whether the company had an attach-rate target. Management said it is already shipping product, has account plans in place, and expects cases to begin immediately, describing the launch as starting from a “warm start” because prior approvals and physician interest already exist. Questions also centered on the legacy CGuard system timeline and CGUARDIANS III; management said it still expects FDA feedback by year-end and continues to target end-2027 for CGUARDIANS III, while also saying the trial is actively enrolling.
The biggest positive is that InspireMD has regained a U.S. commercial path with FDA approval of CGuard Prime for TCAR, which management says roughly doubles the U.S. procedure opportunity. Management also said product is shipping now, physician interest is strong, international demand remains healthy, and the company has already reduced its cost base to support the next phase.
The quarter still showed weak financial performance, with revenue down 11%, gross margin compressed to 10.7%, and cash falling to $19.2 million as the company pursues reentry and development programs. Management also highlighted several execution risks: the financing is still pending, the legacy CAS system still needs FDA feedback, the Prime 135 CAS reentry depends on regulatory review, and future growth depends on converting clinical differentiation into routine commercial adoption.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 60.2%
- Shares Outstanding
- 54.13M
- Float Shares
- 32.60M
of shares held by institutions
38 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rosalind Advisors, Inc. | 3.91M | 0 |
| Aberdeen Group PLC | 3.70M | 0 |
| Nantahala Capital Management, LLC | 3.38M | 0 |
| Orbimed Advisors LLC | 3.13M | 0 |
| Parkman Healthcare Partners LLC | 2.42M | 0 |
| Marshall Wace, Llp | 1.86M | 0 |
| Soleus Capital Management, L.P. | 1.05M | 0 |
| Pura Vida Investments, LLC | 450.52K | 0 |
| Ingalls & Snyder LLC | 362.55K | ▼ 6.25K |
| Velan Capital Investment Management LP | 148.14K | ▼ 1.95M |
| Ubs Group AG | 133.65K | ▲ 128.34K |
| Blackrock, Inc. | 117.71K | ▼ 5.29K |
Held by 7 ETFs
Biggest fund positions in NSPR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Stuka Paul | buy | 30,000 |
| Nov 13, 26 | Stuka Paul | buy | 307,693 |
| Nov 13, 26 | Stuka Paul | buy | 230,769 |
| Nov 13, 26 | Lawless Michael A | buy | 115,385 |
| Nov 13, 26 | Lawless Michael A | buy | 86,539 |
| Nov 13, 26 | BERMAN MICHAEL | buy | 76,923 |
| Nov 13, 26 | BERMAN MICHAEL | buy | 57,692 |
| Nov 13, 26 | Slosman Marvin | buy | 46,154 |
| Nov 13, 26 | Slosman Marvin | buy | 34,616 |
| Nov 13, 26 | ROUBIN GARY S | buy | 153,846 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NSPR coverage
Recent articles, reports, and earnings notes.
No research on NSPR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NSPR report →InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 20
InspireMD, Inc. (NSPR) Discusses Carotid Artery Disease Management and CGuard Prime Clinical Benefits Transcript
seekingalpha.com · Nov 20
InspireMD Announces First U.S. Commercial TCAR Procedures Using the FDA-Approved CGuard® Prime TransCarotid Stent System
globenewswire.com · Nov 18
InspireMD to Host KOL Webinar on Carotid Artery Disease Management and the Clinical Benefits of InspireMD's CGuard Prime Carotid Stent Platform
globenewswire.com · Nov 17
InspireMD (NSPR) Upgraded to Buy: Here's Why
zacks.com · Nov 17
InspireMD Announces Talks Featuring CGuard and CGuard Prime at VEITHsymposium 2026
globenewswire.com · Nov 16
InspireMD Announces Pricing of $37.5 Million Public Offering
globenewswire.com · Nov 13
InspireMD, Inc. (NSPR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.